POLYMORPHISM C3435T OF THE MDR-1 GENE PREDICTS RESPONSE TO PREOPERATIVE CHEMOTHERAPY IN LOCALLY ADVANCED BREAST CANCER WITH HER2/Neu EXPRESSION
|
|
- Abraham Weaver
- 5 years ago
- Views:
Transcription
1 Polymorphism C3435t of The MDR-1 Gene Predicts Response to Preoperative Chemotherapy... (Ami Ashariati) POLYMORPHISM C3435T OF THE MDR-1 GENE PREDICTS RESPONSE TO PREOPERATIVE CHEMOTHERAPY IN LOCALLY ADVANCED BREAST CANCER WITH HER2/Neu EXPRESSION Ami Ashariati Division of Hematology-Medical Oncology, Department of Internal Medicine Airlangga University School of Medicine Dr.Soetomo Teaching Hospital Oncology Hospital Surabaya, Indonesia ABSTRACT P-glycoprotein (mdr-1), encoded by the MDR-1 gene, confers multi-drug resistance against antineoplastic agents and important for the transmembrane transition of various other common therapeutic drugs. Recently, a polymorphism of MDR1 gene at cdna position 3435 located in exon 26 has been shown to be correlated with clinical response to chemotherapy in cancer patients. The Anthracycline therapy, which is related to Her-2 expression in breast cancer patients, has better survival, although the mechanism of cancer cell sensitivity which expressed Her-2 to Anthracycline in its relation to P-glycoprotein expression is still unclear. The purpose of this study was to reveal those mechanisms mentioned above, which in the future could be used as the basic of Anthracycline application in breast cancer patients. An analytical observational research in nineteen patients diagnosed between January until December 2005 with locally advanced breast cancer treated by preoperative Anthracycline chemotherapy to evaluate its predictive outcome was performed. All samples were performed immunohistochemistry, PCR, and sequencing methodology of the MDR1 target gene. The results of this study showed that the polymorphism of MDR1 gene at cdna position 3435 located in exon 26 has been shown to be correlated with clinical response to Anthracycline chemotherapy in breast cancer patients, without affected by positive or negative Her-2 expression. Patient with T/T genotype developed clinical response, while patient with C/T genotype did not develop clinical response. Thus, our study showed that the Breast cancer patients with positive Her-2 expression is not always responsive to Anthracycline application. It means that only patients with T/T genotype at position 3435 located in exon 26 of MDR1 gene that have clinical response, while patients who do not show clinical response having C/T genotype. MDR-1 polymorphism C3435T in exon 26 may co-determine resistance to chemotherapy and provide useful information to individualize therapy. Keywords: Polymorphism C3435T, MDR-1, Her-2, Anthracycline, breast cancer Correspondence: Ami Ashariati, Division of Hematology-Medical Oncology, Department of Internal Medicine Airlangga University School of Medicine, Dr.Soetomo Teaching Hospital, Jl Prof Dr Moestopo 6-8, Surabaya, phone INTRODUCTION The MDR1 gene product P-glycoprotein (P-gp) is a member of the ATP-binding cassette transporter family. P-gp utilizes the energy derived from ATP hydrolysis to pump a wide range of compounds, including numerous clinically used drugs, out of cells. This activity has important pharmacokinetic and pharmacodynamic consequences. For example, P-gp is expressed within the apical membranes of intestinal, renal, and hepatic epithelial cells, where it affects the absorption and elimination of its substrates. P-gp is also located within the apical membranes of capillary endothelial cells of the brain, where it can limit the penetration of drugs to the CNS. In addition to the roles of P-gp in absorption, distribution, and elimination, the over-expression of P- gp is implicated in the development of the multi-drug resistance (MDR) phenotype of some tumor cells. Understanding the functional and clinical consequences of MDR1 variants is important. If this variability could be assigned to a mutation in the MDR1 gene, patients could be screened and appropriate dose adjustments could be made on the basis of their MDR1 genotype (Leonard et al. 2003; Longley & Johnston 2005). Recently, a number of papers have reported the discovery and initial characterization of MDR1 variants. To date, more than 20 mutations in the MDR1 gene have been identified. Until now, however, the functional and clinical consequences of only one common MDR1 variant, C3435T, have been investigated (Dresser 2001). 41
2 Folia Medica Indonesiana Vol. 44 No. 1 January March 2008 : A polymorphism of MDR1 gene has been showed to be correlated with intestinal P-glycoprotein (P-gp) expression and activity in vivo (Hoffmeyer et al. 2000). This polymorphism consists of a C-to-T exchange at cdna position 3435 located in exon 26 of the MDR1 gene. Although this base exchange does not affect the amino acid sequence of P-gp, the T allele appears to be associated with markedly lower MDR1 expression compared with the C allele (Nauck et al. 2000). Because of its silence on the protein level and its location in a non-regulatory region of the MDR1 gene, it is conceivable that this particular polymorphism is not causative for differences in P-gp expression. It is rather likely that this polymorphism is linked to other, as yet unidentified, changes in regions of the MDR1 gene that control expression, e.g., in the promoter/enhancer region or in regions that are relevant for mrna processing. Nevertheless, the C3435T polymorphism appears to allow the differentiation of alleles with distinct MDR-1 expression and activity. Therefore, genotyping of the C3435T polymorphism may provide a basis for treating patients more effectively with agents that are substrates of the MDR-1 gene product, e.g., anticancer drugs such vincristine and doxorubicin (Nauck et al. 2000). The prevalence of breast cancer in Indonesia nowadays has not been known definitely. Breast cancer cases each year have a tendency to increase and most of them come with advanced stage. The management of breast cancer patient now is improving progressively. For the last 2 decades, neoadjuvant or preoperative chemotherapy is developed to become one of the relatively new concepts in locally advanced breast cancer therapy. Many reports stated that the use of neoadjuvant chemotherapy in locally advanced stage breast cancer caused primary tumor regression around 60%-80%. Usually, Anthracycline group (epirubicin/doxorubicin), one of chemotherapy regiments, has good response, about 87%-91%. Component of the chemical compound Anthracycline can react with cytochrome reductase P450 and oxygen to produce superoxide anion radicals (free-radical), which finally may destroy DNA. Anthracyclineexposed-cells can induce apoptosis through the process of caspase activation. In one of the research result, patients with positive Her-2 expression are more responsive to Anthracycline compared with negative Her-2 expression and statistically is significantly different. It was approved that Her-2 expression could be used as predictor biomarker in choosing regiment of medication of Anthracycline group or others (Campiglio & Somenzi 2003; Clahsen et al. 1996; Hortobagyi et al. 1996). About 20%-30% breast cancer patient overexpressed Her-2. The presence of resistance problem in chemotherapy is part of problems in the clinic. There are several factors which influence this resistance i.e (i) mechanism which influence drug activation or inactivation, (ii) drug transport (entry or efflux) by the role of P-glycoprotein (mdr-1) which is produced by MDR-1 gene, (iii) level of target cell which related to DNA repair gene and cell survival pathway (apoptosis, growth factor and it receptor such as HER-2). It is concluded that level of MDR-1 gene expression quantity in malignancy is variable but generally increased. On the contrary, malignancy such as breast cancer has low MDR-1 expression. Although Anthracycline gives better survival and there are relations between Her-2 expression with Anthracycline sensitivity in breast cancer patient, the mechanism of cancer cell sensitivity that expressed Her-2 to anthracycline, if it is related with MDR-1(P-gp) expression, is still unclear. This research attempted to reveal the mechanism of breast cancer resistance, which in the future could be used as the basis of Anthracycline application in breast cancer patient which expressed Her-2 and related with mdr1 expression. MATERIALS AND METHODS Between January until December 2005, nineteen patients diagnosed with locally advanced breast cancer were treated by preoperative anthracycline-based chemotherapy (3-4 cycles). Mean age of the patients that gave their informed consent to the study was 46.5 years (range 20-59) at the time of diagnosis. Tumor size was evaluated by physical examination, ultrasound and mammography at baseline before therapy, and after 3-4 course of chemotherapy or prior to the surgery. According to histopathological examination, all tumors were infiltrating ductal carcinomas. Evaluation of response to treatment was based on the recommended response evaluation criteria in solid tumors (RECIST). Clinical tumor response to preoperative chemotherapy was graded as complete (ccr) partial (cpr), or no response (cnr). Patients who clinically responsive (operable) were operated and those who had no response were subjected to core biopsy. After that, immunohistochemistry, PCR, and sequencing of MDR1 target gene were performed to all samples. Nineteen specimens were obtained after chemotherapy. Immunohistochemical staining was performed using the avidin-biotin peroxidase kit (Vector Laboratories, Burlingame, CA). The sections were deparaffinized in xylene and rehydrated in serial ethanol. Endogenous peroxidase activity was blocked with methanol and 0.3% hydrogen peroxide. Slides were then incubated with 1.5% horse serum at 37 0 C for 20 minutes, and then incubated with monoclonal primary antibodies at 37 0 C for 30 minutes. Murine monoclonal antibody specific for p-glycoprotein, JSB-1 (Sanbio, Am Uden, 42
3 Polymorphism C3435t of The MDR-1 Gene Predicts Response to Preoperative Chemotherapy... (Ami Ashariati) Holland), was used as the primary antibody. Biotinylated secondary antibody was dropped on all slides, which were then incubated at 37 0 C for 30 minutes and washed in phosphate buffered saline (PBS). The slides were then incubated with avidin-biotin complex at room temperature for 30 minutes and washed in PBS. Diaminobenzidine was used as a peroxidase substrate for color development. Multidrug resistant KB-8-5 cells and multidrug sensitve KB-3-1 cells were used as positive and negative controls, respectively. Expression of p-glycoprotein was found in both the cytoplasm and the cell membrane. In cases where there was extremely small number of cells with homogenous and weak cytoplasmic staining, the tumors were categorized as negative. Grades of p-gp expression were arbitrarily determined according to the percent of positive cells against the total number of cancer cells (+; less than 25% cells, ++; 26-50%, +++; 51-75%, ++++; more than 75%). When p-gp was expressed + until +++, we defined it as negative expression criteria, and if p-gp was expressed ++++, we defined it as positive expression criteria. Genomic DNA was isolated from patient s tissue samples with a Qiagen DNA Blood Kit and a 106 bp fragment containing the C3435T polymorphism in exon 26 of the MDR-1 gene was amplified with the primer pair 5 -CCTATGGAGACAACAGCC-3 / 5 - GAGAGACTTACATTAGGCAG-3. The quality of PCR products was checked by agarose gel electrophoresis. Strands of the PCR product were separated by incubation of the beads with 50 µl 0.2 M NaOH for 1 min followed by two washes with 150 µl 10 mm Tris acetate. Table 1. The Characteristic of Breast Cancer patients Median age (range) 46.5 (20-59) Performance Status (ECOG) 100% 19 (100%) Tumor Size & lymhnode status T3 N1-2 9 (47%) T4 N (53%) Pathological characteristics Ductal invasive carcinoma 19 (100%) Pathological grade Grade III 19 (100%) Hormonal Receptors ER+/PR+ 5 (26%) ER+/PR- 0 ER-/PR+ 1 (5%) ER-/PR- 13 (69%) Her2 status positive 11 (58%) negative 8 (42%) Table 2. Distribution of Clinical Response and Her2 Expression Expression cresponse (+) cresponse (-) Total (%) Her2 (+) (58) Her2 (-) (42) Total (%) 14 (73.6) 5 (26.4) 19 (100) (Fischer exact test p=1.000) RESULTS Based on RECIST criteria, ccr was not observed but cpr in 14 (74%) resulting in an overall rate of clinical response to preoperative chemotherapy and 5 (26%) cnc was observed in the other patients. Based on immunohistochemical test, Her2 expression was observed in 11(58%) of patients and 8(42%) of patients showed negative Her2 expression. The genotypes of all 19 patients at position C3435 in exon 26 of MDR-1 gene were determined by PCR sequencing methodology. The C/T genotype occurred in 5 (26%) of the subjects, while the others were homozygous T/T (74%). Most of the patients (74%) with a T/T genotype responded clinically to preoperative chemotherapy, but the group possessing C/T genotype did not respond clinically to preoperative chemotherapy. Statistical analysis revealed non-significant correlation (p=1.000) between clinical response and the T/T genotype. agattgtga fragments-sequence (T/T genotype) agatcgtga fragments Sequence (C/T genotype) Figure 1. Electrophoregram MDR1 gene at position 3435 located in exon 26 of breast cancer from this study 43
4 Folia Medica Indonesiana Vol. 44 No. 1 January March 2008 : agatcgtga fragment-sequence (C/T genotype) agattgtga fragmen-sequence (T/T genotype) Figure 2. Electrophoregram of MDR1 gene at position 3435 located in exon 26 of Breast cancer from study of Illmer T, DISCUSSION The in vivo model of preoperative chemotherapy has proved to be useful to investigate novel therapeutic concepts and evaluate new predictive and prognostic factors. Bonadonna and Fisher et al. (as cited in Kafka et al. 2003), clearly demonstrated that response to preoperative chemotherapeutic treatment is an important indicator of both disease-free and overall survival. The identification of new predictor factors for response to preoperative chemotherapy may, therefore, help to define subgroups of patients that most likely benefit from this type of therapeutic approach. Numerous drug resistance-associated genes have been described. However, their precise roles in the development of resistance to chemotherapy observed in the different types of human tumors still remain to be elucidated. This true even for the most extensively studied MDR-1 gene that was first discovered as a factor mediating multi-drug resistance in cancer chemotherapy. Its genes product P-gp was found to reduce the bioavailability of various compounds at the cellular level. Conferring multi-drug resistance to several types of tumors cells, MDR-1 expression and P- gp function is considered to contribute to cellular events that determine cancer patient s resistance to chemotherapy (Kafka et al. 2003). Several other investigations (Duhem et al. 1996; Ejendal & Hrycyna 2002; Illmer 2002; Kafka et al. 2003) point to an implication of the MDR-1 genes in the manifestation of resistant phenotypes in locally advanced breast cancer treated by preoperative chemotherapy that codetermines the clinical outcome. Furthermore, MDR-1 expression induced by chemotherapy of locally advanced breast cancer was also found to be an indicator of a worse long-term prognosis. Kafka et al. (2003) assessed MDR-1 expression sequentially during preoperative chemotherapy and also demonstrated a significant correlation with response to treatment. If we take a good look, some theories saying mdr-1 expression is one of the factors that influence the chemotherapy resistance, are yet to be proven in this research. It is still unknown, whether this clinical response is caused by other factor, such as mdr-1 expression level that is encoded by MDR-1 gene, that might have an ability to determine which one is recognized matter or not and then being transported more effectively. For the last 2 decades, neo-adjuvant or preoperative chemotherapy is developed to become one of the relatively new concepts in locally advanced breast cancer therapy. Many reports stated that the use of neoadjuvant chemotherapy in locally advanced stage breast cancer caused primary tumor regression around 60%- 80%. Usually, anthracycline group (epirubicin/ doxorubicin) has good response, about 87%-91% (Campiglio & Somenzi 2003; Childs et al. 2002; Clahsen et al. 1996). In one of the research result, patient with positive Her-2 expression are more responsive to anthracycline compared with negative Her-2 expression and statistically is significantly different. It was approved that Her-2 expression could be used as prediction biomarker in choosing regiment of medication of Anthracycline group or others (Clahsen et al. 1996). Although anthracycline gives better survival and there are relations between Her-2 expression with anthracycline sensitivity in breast cancer patient, the mechanism of cell cancer sensitivity which expressed Her-2 to anthracycline if it is related with MDR-1(P-gp) expression is still unclear. One of the factors that influence chemotherapy-response is the variation at some MDR-1 genome area. Apparently MDR-1 gene located in exon 26 is found to have several variations. A polymorphism of MDR1 44
5 Polymorphism C3435t of The MDR-1 Gene Predicts Response to Preoperative Chemotherapy... (Ami Ashariati) gene has been shown to be correlated with intestinal P- glycoprotein (P-gp) expression and in vivo activity (Hoffmeyer et al. 2000). This polymorphism consists of a C-to-T exchange at cdna position 3435 located in exon 26 of the MDR1 gene. Although this base exchange does not affect the amino acid sequence of P- gp, the T allele (T/T genotype) appears to be associated with markedly lower MDR1 expression compared with the C allele (C/T genotype) (Hoffmeyer et al. 2000; Nauck et al. 2000; Schneider et al. 2001). Because of its silence on the protein level and its location in a nonregulatory region of the MDR1 gene, it is conceivable that this particular polymorphism is not causative for differences in P-gp expression. It is rather likely that this polymorphism is linked to other, as yet unidentified, changes in regions of the MDR1 gene that control expression, e.g., in the promoter / enhancer region or in regions that are relevant for mrna processing. Nevertheless, the C3435T polymorphism appears to allow the differentiation of alleles with distinct MDR-1 expression and activity. Therefore, genotyping of the C3435T polymorphism may provide a basis for treating patients more effectively with agents that are substrates of the MDR-1 gene product, e.g., anticancer drugs such vincristine and doxorubicin (Nauck et al. 2000). In Kafka et al. study (2003), rates of clinical and histopathological response to preoperative chemotherapy were comparable to the results of the other neoadjuvant trial. We determined the genotypes at position 3435 located in exon 26 of the MDR-1 gene in the patients. Remarkably, statistical analysis revealed a significant correlation between the T/T genotype and clinical response of the patients to preoperative chemotherapy. This correlation may be explained by genotype-dependent expression of P-gp that was demonstrated recently by Hoffmeyer et al. (2000). Although it is not obvious how expression is affected by the C3435T polymorphism that is not causing any variability in amino acid sequence (because C3435T is a silent mutation), MDR-1 expression in intestinal biopsies (n=21) was found to be 2-fold lower in individuals with a T/T genotype compared those possessing C/C genotype (Dresser 2001; Kafka et al. 2003). A similar correlation between final clinical outcome and MDR-1 exon 26 variants was recently reported for patients suffering from acute myeloic leukemia (Illmer 2002). Our results showed that the difference in clinical response of breast cancer patients caused by variation of MDR-1 gene exon 26 on 3435 position, which can make difference in clinical response without affecting the positive or negative Her-2 expression. Patients with T/T genotype had clinical response, while patients who do not show clinical response having C/T genotype. Our results and other reports pointing to a correlation of single nucleotide polymorphism in the MDR-1 gene and expression or function of P-gp contribute to the information on genetic background that may be relevant to predict the individual outcome in therapeutic approaches with drugs that are affected by P-gp. REFERENCES Campiglio, M & Somenzi, G 2003, Role of proliferation in HER-2 status predicted response to Doxorubicin, Int J Cancer, vol. 105, no. 4, pp Childs, AC, Phaneuf, SL, Dirks, AJ, Phillips, T, Leeuwenburgh, C 2002, Doxorubicin treatment in vivo causes Cytochrome c release and cardiomyocyte apoptosis, as well as Increased mitochondrial efficiency, superoxide Dismutase activity, and Bcl-2 : Bax ratio, Cancer Research, vol. 62, pp Clahsen, PC et al. 1996, Improved Local control and disease free survival after neoadjuvant chemotherapy to Early Stage Breast Cancer: A European organization for research and treatment of Cancer Cooperative Group Study, J Clin Oncol, vol. 14, no.3, pp Dresser, MJ 2001, The MDR1 C3435T polymorphism: Effect on P-glycoprotein expression/function and clinical significance, AAPS PharmSci, vol. 3. no. 3, Commentary 3, retrieved February 1, 2006, from aapspharmsci.org Duhem, C, Ries, F, Dicato, M 1996, What does Multidrug Resistance (MDR) expression mean in the clinic?, The Oncologist J, vol. 1, pp Ejendal, K & Hrycyna, CA 2002, Multidrug resistance and cancer: The role of the human ABC Transporter ABCG2, Current Protein and Peptide Science, vol. 3, pp Hortobagyi, GN, Singletary, SE, McNeese, MD 1996, Treatment of Locally Advanced and Inflammatory Breast Cancer Disease of the Breast, JR Haris & ME Lippman et al. (edn), Philadelphia, Lippincott-Raven, NewYork, pp Hoffmeyer, S, Burk, O, Ricther, O et al. 2000, Functional polymorphisms of the human multidrug resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo, PNAS, vol. 97, pp Illmer, T, Schuler, US, Thiede, C 2002, MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients, Cancer Research, vol. 62, pp Kafka, A, Sauer, G, Jaeger, C et. al. 2003, Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally 45
6 Folia Medica Indonesiana Vol. 44 No. 1 January March 2008 : advanced breast cancer, International J of Oncol, vol. 22, pp Leonard, GD, Fojo, T, Bates, SE 2003, The role of ABC transporters in clinical practice, The Oncologist, vol. 8, pp Longley, DB & Johnston, PG 2005, Molecular mechanisms of drug resistance, J Pathol, vol. 205, pp Nauck, M, Stein, U, Karger, S et al. 2000, Rapid detection of C3435T polymorphism of multidrug resistance gene 1 using fluorogenic hybridation probes, Clin Chemistry, vol. 46, pp Schneider, J, Gonzalez-Roces, S, et al. 2001, Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemtherapy, Breast Cancer Res, vol. 3, pp
Polymorphism C3435T of The MDR-1 Gene Predict Response to Preoperative Chemotherapy in Locally Advanced Breast Cancer with Her2/neu Expression
ORIGINAL ARTICLE Polymorphism C3435T of The MDR-1 Gene Predict Response to Preoperative Chemotherapy in Locally Advanced Breast Cancer with Her2/neu Expression Ami Ashariati ABSTRACT Aim: to reveal the
More informationA Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast
Original Research Article A Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast E. Rajesh Goud 1, M. Muralidhar 2*, M. Srinivasulu 3 1Senior
More informationCase Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.
Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to
More informationMRP1 polymorphisms (T2684C, C2007T, C2012T, and C2665T) are not associated with multidrug resistance in leukemic patients
MRP1 polymorphisms (T2684C, C2007T, C2012T, and C2665T) are not associated with multidrug resistance in leukemic patients F. Mahjoubi, S. Akbari, M. Montazeri and F. Moshyri Clinical Genetics Department,
More information(A) PCR primers (arrows) designed to distinguish wild type (P1+P2), targeted (P1+P2) and excised (P1+P3)14-
1 Supplemental Figure Legends Figure S1. Mammary tumors of ErbB2 KI mice with 14-3-3σ ablation have elevated ErbB2 transcript levels and cell proliferation (A) PCR primers (arrows) designed to distinguish
More informationAccuracy of MRI in the Detection of Residual Breast Cancer after Neoadjuvant Chemotherapy
Med. J. Cairo Univ., Vol. 85, No. 4, June: 1411-1416, 2017 www.medicaljournalofcairouniversity.net Accuracy of MRI in the Detection of Residual Breast Cancer after Neoadjuvant Chemotherapy MONA A. ABUL-ENEIN,
More informationBarriers to Understanding
Behind the Scenes: The Critical Importance of Cancer Cell Pathology and the Pathologist Sherry T. Emery, M.D., Chief of Pathology Northeast Health System Barriers to Understanding Questions for 2010 What
More informationDOCTORAL THESIS SUMMARY
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA FACULTY OF MEDICINE DOCTORAL THESIS SUMMARY CLINICO-IMAGING STUDY OF INVASIVE DUCTAL BREAST CARCINOMAS CORRELATED TO HORMONAL RECEPTORS AND HER2/NEU ONCOPROTEIN
More informationDNA Methylation of Tumor Suppressor and Metastasis Suppressor Genes in Circulating Tumor Cells and corresponding Circulating Tumor DNA
DNA Methylation of Tumor Suppressor and Metastasis Suppressor Genes in Circulating Tumor Cells and corresponding Circulating Tumor DNA Maria Chimonidou 1, Areti Strati 1, Nikos Malamos 2, Vasilis Georgoulias
More informationEffect of variation of ABCB1 and GSTP1 on osteosarcoma survival after chemotherapy
Effect of variation of ABCB1 and GSTP1 on osteosarcoma survival after chemotherapy J.Z. Li 1, Z.Q. Tian 2, S.N. Jiang 3 and T. Feng 4 1 Department of Orthopedics, Juye County People s Hospital, Heze, China
More informationmicrorna Presented for: Presented by: Date:
microrna Presented for: Presented by: Date: 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions
More informationProblems in staging breast carcinoma
Problems in staging breast carcinoma Primary systemic therapy (PST) of breast carcinoma pathologists tasks Dr. Janina Kulka, 2nd Department of Pathology, Semmelweis University Budapest Austro-Hungarian
More informationCancer cells in vitro
Supplementary Figure S1 Cancer cells in vitro Pretreatment with Control IgG (18h) Pretreatment with anti-u-par (18h) Acid Wash/Pretreatment with Control IgG (18h) Acid Wash/Pretreatment with anti-u-par
More informationDr. dr. Primariadewi R, SpPA(K)
Curriculum Vitae Dr. dr. Primariadewi R, SpPA(K) Education : Medical Doctor from UKRIDA Doctoral Degree from Faculty of Medicine University of Indonesia Pathologist Specialist and Consultant from Faculty
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationGastric Carcinoma with Lymphoid Stroma: Association with Epstein Virus Genome demonstrated by PCR
Gastric Carcinoma with Lymphoid Stroma: Association with Epstein Virus Genome demonstrated by PCR Pages with reference to book, From 305 To 307 Irshad N. Soomro,Samina Noorali,Syed Abdul Aziz,Suhail Muzaffar,Shahid
More informationChanges in Protein Expression in Breast Cancer after Anthracycline- Based Chemotherapy
The Korean Journal of Pathology 2007; 41: 165-70 Changes in Protein Expression in Breast Cancer after Anthracycline- Based Chemotherapy Ho-chang Lee JaeOk Lee 1 In Ae Park Department of Pathology, Seoul
More informationEstrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women
Journal of Bangladesh College of Physicians and Surgeons Vol. 28, No. 3, September 2010 Estrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women
More informationBcl-2 and p53 protein expression in all grades of astrocytomas
Southern Adventist Univeristy KnowledgeExchange@Southern Senior Research Projects Southern Scholars 11-1994 Bcl-2 and p53 protein expression in all grades of astrocytomas Robyn L. Castleberg Follow this
More informationThe Biology and Genetics of Cells and Organisms The Biology of Cancer
The Biology and Genetics of Cells and Organisms The Biology of Cancer Mendel and Genetics How many distinct genes are present in the genomes of mammals? - 21,000 for human. - Genetic information is carried
More informationBreast cancer. Risk factors you cannot change include: Treatment Plan Selection. Inferring Transcriptional Module from Breast Cancer Profile Data
Breast cancer Inferring Transcriptional Module from Breast Cancer Profile Data Breast Cancer and Targeted Therapy Microarray Profile Data Inferring Transcriptional Module Methods CSC 177 Data Warehousing
More informationBasement membrane in lobule.
Bahram Memar, MD Basement membrane in lobule. Normal lobule-luteal phase Normal lobule-follicular phase Lactating breast Greater than 95% are adenocarcinomas in situ carcinomas and invasive carcinomas.
More informationP atients with primary breast cancer have an increased risk of developing contralateral breast cancer1. When
OPEN SUBJECT AREAS: BONE METASTASES BREAST CANCER Received 23 July 2013 Accepted 19 August 2013 Published 5 September 2013 Correspondence and requests for materials should be addressed to C.W.D. (ducaiwen@
More information1.5. Research Areas Treatment Selection
1.5. Research Areas Cancer biomarker research embraces many areas of study, including tumorigenesis, metastasis, clinical trial and surrogate endpoints, cell isolation, target identification, drug resistance,
More informationBreast Cancer? Breast cancer is the most common. What s New in. Janet s Case
Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of
More informationReview of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
More informationFGL2 A new biomarker for cancer in a simple blood test
FGL2 A new biomarker for cancer in a simple blood test WHO IS FGL2 Human gene (chromosome 7) is 7 kb long, 2 exons, monomer protein 70 KD, tetramer in solution. Fibrinogen-like protein 2 (Fgl2), a member
More informationRESEARCH ARTICLE. Expression of LRP Gene in Breast Cancer Patients Correlated with MRP1 as Two Independent Predictive Biomarkers in Breast Cancer
DOI:10.31557/APJCP.2018.19.11.3111 RESEARCH ARTICLE Editorial Process: Submission:01/03/2018 Acceptance:09/24/2018 Expression of LRP Gene in Breast Cancer Patients Correlated with MRP1 as Two Independent
More informationThe importance of pharmacogenetics in the treatment of epilepsy
The importance of pharmacogenetics in the treatment of epilepsy Öner Süzer and Esat Eşkazan İstanbul University, Cerrahpaşa Faculty of Medicine, Department of Pharmacology and Clinical Pharmacology Introduction
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationCorrelation Between GATA-3, Ki67 and p53 Expressions to Histopathology Grading of Breast Cancer in Makassar, Indonesia
Cancer Research Journal 2016; 4(3): 43-47 http://www.sciencepublishinggroup.com/j/crj doi: 10.11648/j.crj.20160403.11 ISSN: 2330-8192 (Print); ISSN: 2330-8214 (Online) Correlation Between GATA-3, Ki67
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More informationFAQs for UK Pathology Departments
FAQs for UK Pathology Departments This is an educational piece written for Healthcare Professionals FAQs for UK Pathology Departments If you would like to discuss any of the listed FAQs further, or have
More informationDevelopment of Drug Resistance and Strategies to Circumvent it: A Brief Look
Development of Drug Resistance and Strategies to Circumvent it: A Brief Look Jin-Ming Yang, MD, PhD The Cancer Institute of New Jersey Department of Pharmacology UMDNJ-Robert Wood Johnson Medical School
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationPatterns of E.cadherin and Estrogen receptor Expression in Histological Sections of Sudanese Patients with Breast Carcinoma
Patterns of E.cadherin and Estrogen receptor Expression in Histological Sections of Sudanese Patients with Breast Carcinoma Hadia. Mohammed. Abdalla. Abdalrhman *, Elsadig.A.Adam, Ayda.D.A.Allatif 3,'Namareg.E.Afadul
More informationTriple Negative Breast Cancer
Triple Negative Breast Cancer Prof. Dr. Pornchai O-charoenrat Division of Head-Neck & Breast Surgery Department of Surgery Faculty of Medicine Siriraj Hospital Breast Cancer Classification Traditional
More informationXMRV among Prostate Cancer Patients from the Southern United States and Analysis of Possible Correlates of Infection
XMRV among Prostate Cancer Patients from the Southern United States and Analysis of Possible Correlates of Infection Bryan Danielson Baylor College of Medicine Department of Molecular Virology and Microbiology
More informationMdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often
More informationHypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression are associated with poor survival in breast cancer patients
Journal of BUON 17: 663-668, 2012 2012 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Hypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression are associated with poor
More informationGenetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma
Genetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma M.J. Wang, Y. Zhu, X.J. Guo and Z.Z. Tian Department of Orthopaedics, Xinxiang Central Hospital, Xinxiang,
More informationIntroduction to Genetics
Introduction to Genetics Table of contents Chromosome DNA Protein synthesis Mutation Genetic disorder Relationship between genes and cancer Genetic testing Technical concern 2 All living organisms consist
More informationCell Culture. The human thyroid follicular carcinoma cell lines FTC-238, FTC-236 and FTC-
Supplemental material and methods Reagents. Hydralazine was purchased from Sigma-Aldrich. Cell Culture. The human thyroid follicular carcinoma cell lines FTC-238, FTC-236 and FTC- 133, human thyroid medullary
More informationUtility of Adequate Core Biopsy Samples from Ultrasound Biopsies Needed for Today s Breast Pathology
Utility of Adequate Core Biopsy Samples from Ultrasound Biopsies Needed for Today s Breast Pathology Ugur Ozerdem, M.D. 1 Abstract Background: There is a paradigm shift in breast biopsy philosophy. In
More informationTable S2. Expression of PRMT7 in clinical breast carcinoma samples
Table S2. Expression of PRMT7 in clinical breast carcinoma samples (All data were obtained from cancer microarray database Oncomine.) Analysis type* Analysis Class(number sampels) 1 2 3 4 Correlation (up/down)#
More informationCirculating Tumor DNA in GIST and its Implications on Treatment
Circulating Tumor DNA in GIST and its Implications on Treatment October 2 nd 2017 Dr. Ciara Kelly Assistant Attending Physician Sarcoma Medical Oncology Service Objectives Background Liquid biopsy & ctdna
More informationQuantification of early stage lesions for loss of p53 should be shown in the main figures.
Reviewer #1 (Remarks to the Author): Expert in prostate cancer The manuscript "Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers" uses a number of novel genetically engineered
More informationFigure S1. Generation of inducible PTEN deficient mice and the BMMCs (A) B6.129 Pten loxp/loxp mice were mated with B6.
Figure S1. Generation of inducible PTEN deficient mice and the BMMCs (A) B6.129 Pten loxp/loxp mice were mated with B6.129-Gt(ROSA)26Sor tm1(cre/ert2)tyj /J mice. To induce deletion of the Pten locus,
More informationCharacterization and significance of MUC1 and c-myc expression in elderly patients with papillary thyroid carcinoma
Characterization and significance of MUC1 and c-myc expression in elderly patients with papillary thyroid carcinoma Y.-J. Hu 1, X.-Y. Luo 2, Y. Yang 3, C.-Y. Chen 1, Z.-Y. Zhang 4 and X. Guo 1 1 Department
More informationRegarding techniques of proteomics, there is:
Molecular الحلقة biology 14 واألخيرة To put you back in the context; the discussion was about Trancriptomics (the study of transcription). The following topic will be PROTEOMICS, which is the study of
More informationSupplementary Information Titles Journal: Nature Medicine
Supplementary Information Titles Journal: Nature Medicine Article Title: Corresponding Author: Supplementary Item & Number Supplementary Fig.1 Fig.2 Fig.3 Fig.4 Fig.5 Fig.6 Fig.7 Fig.8 Fig.9 Fig. Fig.11
More informationDoes HER2/neu overexpression in breast cancer influence adjuvant chemotherapy and hormonal therapy choices by Ontario physicians? A physician survey
MYERS et al. ORIGINAL ARTICLE Does HER2/neu overexpression in breast cancer influence adjuvant chemotherapy and hormonal therapy choices by Ontario physicians? A physician survey J.A. Myers MD FRCPC, G.
More informationNeoplasia 2018 lecture 11. Dr H Awad FRCPath
Neoplasia 2018 lecture 11 Dr H Awad FRCPath Clinical aspects of neoplasia Tumors affect patients by: 1. their location 2. hormonal secretions 3. paraneoplastic syndromes 4. cachexia Tumor location Even
More informationCANCER. Clinical Validation of Breast Cancer Predictive Markers
Clinical Validation of Breast Cancer Predictive Markers David Hicks, MD Loralee McMahon, MS, HTL(ASCP) CANCER The human body is composed of billions of highly regulated cells Cancer cells no longer respond
More informationRCD24, B7-H4 and PCNA expression and clinical significance in ovarian cancer
JBUON 2019; 24(2): 715-719 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE RCD24, B7-H4 and PCNA expression and clinical significance in ovarian
More informationRole of Paired Box9 (PAX9) (rs ) and Muscle Segment Homeobox1 (MSX1) (581C>T) Gene Polymorphisms in Tooth Agenesis
EC Dental Science Special Issue - 2017 Role of Paired Box9 (PAX9) (rs2073245) and Muscle Segment Homeobox1 (MSX1) (581C>T) Gene Polymorphisms in Tooth Agenesis Research Article Dr. Sonam Sethi 1, Dr. Anmol
More informationBreast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C, Heidel RE, Desai P, McLoughlin J, Panella T, Bell
More informationBreast cancer in Brunei Darussalam Differential community distribution and an analysis of common molecular tumour markers
Breast cancer markers Breast cancer in Brunei Darussalam Differential community distribution and an analysis of common molecular tumour markers Foo Ren Kang, PU Telesinghe, Syaffiq bin Abdallah, and R.
More informationAnticancer Drugs. University of Sulaimani Faculty of Medical Sciences School of Pharmacy Pharmacology & Toxicology Dept.
University of Sulaimani Faculty of Medical Sciences School of Pharmacy Pharmacology & Toxicology Dept. Anticancer Drugs Prepared by: Hussein A. Muhammad MSc cancer Pharmacology hussein.al-barazanchi@kissr.edu.krd
More informationDepartment of Endocrine & Breast Surgery Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
Department of Endocrine & Breast Surgery Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India Evidence-Based Pragmatic SGPGI Breast Cancer Management Protocols (Summary) Background:
More informationMaurizio D Incalci, MD Department of Oncology Mario Negri Institute, Milan, Italy
Maurizio D Incalci, MD Department of Oncology Mario Negri Institute, Milan, Italy Oncologic Therapy Personalization: from basic research to clinical application Limits of: BASIC RESEARCH Reggio Emilia,
More informationImmunohistochemical studies (ER & Ki-67) in Proliferative breast lesions adjacent to malignancy
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 13, Issue 3 Ver. IV. (Mar. 2014), PP 84-89 Immunohistochemical studies (ER & Ki-67) in Proliferative
More informationAbsence of Kaposi s Sarcoma-Associated Herpesvirus in Patients with Pulmonary
Online Data Supplement Absence of Kaposi s Sarcoma-Associated Herpesvirus in Patients with Pulmonary Arterial Hypertension Cornelia Henke-Gendo, Michael Mengel, Marius M. Hoeper, Khaled Alkharsah, Thomas
More informationHuman Cathepsin D ELISA Kit
GenWay Biotech, Inc. 6777 Nancy Ridge Drive San Diego, CA 92121 Phone: 858.458.0866 Fax: 858.458.0833 Email: techline@genwaybio.com http://www.genwaybio.com Human Cathepsin D ELISA Kit Catalog No. GWB-J4JVV9
More informationMETRIC Study Key Eligibility Criteria
The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).
More informationMRC-Holland MLPA. Description version 06; 23 December 2016
SALSA MLPA probemix P417-B2 BAP1 Lot B2-1216. As compared to version B1 (lot B1-0215), two reference probes have been added and two target probes have a minor change in length. The BAP1 (BRCA1 associated
More informationGenetics and Genomics: Influence on Individualization of Medication Regimes
Genetics and Genomics: Influence on Individualization of Medication Regimes Joseph S Bertino Jr., Pharm.D., FCCP Schenectady, NY USA Goals and Objectives To discuss pharmacogenetics and pharmacogenomics
More information(Stratagene, La Jolla, CA) (Supplemental Fig. 1A). A 5.4-kb EcoRI fragment
SUPPLEMENTAL INFORMATION Supplemental Methods Generation of RyR2-S2808D Mice Murine genomic RyR2 clones were isolated from a 129/SvEvTacfBR λ-phage library (Stratagene, La Jolla, CA) (Supplemental Fig.
More informationAbhd2 regulates alveolar type Ⅱ apoptosis and airway smooth muscle remodeling: a key target of COPD research
Abhd2 regulates alveolar type Ⅱ apoptosis and airway smooth muscle remodeling: a key target of COPD research Shoude Jin Harbin Medical University, China Background COPD ------ a silent killer Insidious,
More informationSystemic Therapy Considerations in Inflammatory Breast Cancer
Systemic Therapy Considerations in Inflammatory Breast Cancer Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau,
More informationThe feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients
The feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients ASSC Scientific Meeting 13 th October 2016 Prof Andrew Barbour UQ SOM
More informationMicroRNA expression profiling and functional analysis in prostate cancer. Marco Folini s.c. Ricerca Traslazionale DOSL
MicroRNA expression profiling and functional analysis in prostate cancer Marco Folini s.c. Ricerca Traslazionale DOSL What are micrornas? For almost three decades, the alteration of protein-coding genes
More informationSupplementary Figure 1. Genotyping strategies for Mcm3 +/+, Mcm3 +/Lox and Mcm3 +/- mice and luciferase activity in Mcm3 +/Lox mice. A.
Supplementary Figure 1. Genotyping strategies for Mcm3 +/+, Mcm3 +/Lox and Mcm3 +/- mice and luciferase activity in Mcm3 +/Lox mice. A. Upper part, three-primer PCR strategy at the Mcm3 locus yielding
More informationContemporary Classification of Breast Cancer
Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline
More informationPHARMACOGENETICS OF BREAST CANCER
PHARMACOGENETICS OF BREAST CANCER MALGORZATA JAREMKO, PhD Mount Sinai School of Medicine, Department of Genetics and Genomic Sciences Outlines Breast cancer therapeutic situation Pharmacogenetics of antiestrogen
More informationDevelopment of Carcinoma Pathways
The Construction of Genetic Pathway to Colorectal Cancer Moriah Wright, MD Clinical Fellow in Colorectal Surgery Creighton University School of Medicine Management of Colon and Diseases February 23, 2019
More informationPredictive Assays in Radiation Therapy
Outline Predictive Assays in Radiation Therapy Radiation Biology Introduction Early predictive assays Recent trends in predictive assays Examples for specific tumors Summary Lecture 4-23-2014 Introduction
More informationIntroduction. Approximately 20% of invasive breast cancers
Introduction Approximately 2% of invasive breast cancers overexpress HER2 The current standard of care for neoadjuvant therapy is dual-targeted therapy with trastuzumab and pertuzumab plus chemotherapy
More informationSupplementary Online Content
Supplementary Online Content Fumagalli D, Venet D, Ignatiadis M, et al. RNA Sequencing to predict response to neoadjuvant anti-her2 therapy: a secondary analysis of the NeoALTTO randomized clinical trial.
More informationMolecular classification of breast cancer implications for pathologists. Sarah E Pinder
Molecular classification of breast cancer implications for pathologists Sarah E Pinder Courtesy of CW Elston Histological types Breast Cancer Special Types 17 morphological special types 25-30% of all
More informationEducational Goals and Objectives for Rotations on: Breast, Wound and Plastic Surgery
Educational Goals and Objectives for Rotations on: Breast, Wound and Plastic Surgery Goal The goal of the Breast Surgery rotation is to develop the knowledge, skills and attitudes necessary to evaluate,
More informationResidual cancer burden in locally advanced breast cancer: a superior tool
ABSTRACT Objectives Locally advanced breast cancer (LABC) poses a difficult clinical challenge with an overall poor long-term prognosis. The strength of the association between tumour characteristics,
More informationIDENTIFICATION OF BIOMARKERS FOR EARLY DIAGNOSIS OF BREAST CANCER"
IDENTIFICATION OF BIOMARKERS FOR EARLY DIAGNOSIS OF BREAST CANCER" Edmond Marzbani, MD December 2, 2008 Early diagnosis of cancer Many solid tumors are potentially curable if diagnosed at an early stage
More informationBreast Cancer Statistics
1 in 8 Breast Cancer Statistics Incidence Mortality Prevalence 2 Breast Cancer Incidence Breast Cancer Mortality Breast Cancer Prevalence ~$100,000 Female Breast Anatomy Breasts consist mainly of fatty
More informationDoctor of Philosophy
Regulation of Gene Expression of the 25-Hydroxyvitamin D la-hydroxylase (CYP27BI) Promoter: Study of A Transgenic Mouse Model Ivanka Hendrix School of Molecular and Biomedical Science The University of
More information[Abstract] Objective: Investigate the effect of KLT on the expression of Fas/Apo-1, FasL and PCNA genes in renal carcinoma cell line (GRC-1).
Study on Effect of Kanglaite Injection(KLT) on the Expression of Fas/Apo-1, FasL and PCNA in Renal Carcinoma Cell Lines Wang Junjie, Sun Xinchen, Sheng Wenjiang, Yu Lizhang [Abstract] Objective: Investigate
More informationPrevalence and clinical implications of BRCA1/2 germline mutations in Chinese women with breast cancer Yuntao Xie M.D., Ph.D.
Prevalence and clinical implications of BRCA1/2 germline mutations in Chinese women with breast cancer Yuntao Xie M.D., Ph.D. Hereditary Cancer Center, Peking University Cancer Hospital 1 Breast cancer
More informationStudying The Role Of DNA Mismatch Repair In Brain Cancer Malignancy
Kavya Puchhalapalli CALS Honors Project Report Spring 2017 Studying The Role Of DNA Mismatch Repair In Brain Cancer Malignancy Abstract Malignant brain tumors including medulloblastomas and primitive neuroectodermal
More informationBIOL 4374/BCHS 4313 Cell Biology Exam #1 February 13, 2001
BIOL 4374/BCHS 4313 Cell Biology Exam #1 February 13, 2001 SS# Name This exam is worth a total of 100 points. The number of points each question is worth is shown in parentheses. Good luck! 1. (2) The
More informationBREAST SURGERY PROGRESS TEST Name:
General Surgery Residency Program Excellent surgeons BREAST SURGERY PROGRESS TEST Name: Choose the BEST answer for the following questions. 1. All of the following factors are associated with an increased
More informationInfluence of ERCC2 gene polymorphisms on the treatment outcome of osteosarcoma
Influence of ERCC2 gene polymorphisms on the treatment outcome of osteosarcoma Z.F. Liu, A.L.J. Asila, K. Aikenmu, J. Zhao, Q.C. Meng and R. Fang Department of Orthopaedics, Chinese Medicine Hospital of
More informationGene expression of follicle-stimulating hormone receptors in granulosa cells in poor ovarian responders
Journal of Physics: Conference Series PAPER OPEN ACCESS Gene expression of follicle-stimulating hormone receptors in granulosa cells in poor ovarian responders To cite this article: P A Iffanolida et al
More informationCitation for published version (APA): Bleeker, W. A. (2001). Therapeutic considerations in Dukes C colon cancer s.n.
University of Groningen Therapeutic considerations in Dukes C colon cancer Bleeker, Willem Aldert IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite
More informationOral Communications & Posters
Carcinoma uroteliale: Current and future directions of treatment of Muscle-Invasive Bladder cancer/ Multimodality approach of bladder cancer Oral Communications & Posters CRISTINA MASINI Oncologia Medica
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More informationHigh expression of fibroblast activation protein is an adverse prognosticator in gastric cancer.
Biomedical Research 2017; 28 (18): 7779-7783 ISSN 0970-938X www.biomedres.info High expression of fibroblast activation protein is an adverse prognosticator in gastric cancer. Hu Song 1, Qi-yu Liu 2, Zhi-wei
More informationshehab Moh Tarek ... ManarHajeer
3 shehab Moh Tarek... ManarHajeer In the previous lecture we discussed the accumulation of oxygen- derived free radicals as a mechanism of cell injury, we covered their production and their pathologic
More information